Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714067 | 0.94 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL4759603 | 0.94 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL26187571 | 0.94 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL15028271 | 0.91 | LMNA (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL6024565 | 0.90 | BLM (0.44) | BLMLMNAPTPN1DGKA | |
| SCHEMBL23761111 | 0.88 | BLM (0.43) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL2352236 | 0.87 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL2347747 | 0.87 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL3859719 | 0.87 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B | |
| SCHEMBL2352043 | 0.87 | BLM (0.48) | BLMLMNAPTPN1PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151282-A1 | AMPHOTERIC LIPOSOME FORMULATIONS | MARINA BIOTECH INC (US) | 2016-06-02 | — | — | US | disclosed |
| US-9283186-B2 | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | MARINA BIOTECH, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140178462-A1 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS | MARINA BIOTECH, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2462924-A2 | Improvements in or relating to amphoteric liposomes. | Marina Biotech, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120135065-A1 | Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome | MARINA BIOTECH, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20100330154-A1 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS | MARINA BIOTECH, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20080088046-A1 | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | NOVOSOM AG (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080089932-A1 | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | MARINA BIOTECH, INC. | 2008-04-17 | — | — | US | disclosed |
| EP-1911443-A1 | Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | Novosom AG (DE) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135065-A1 | Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome | LIPA, SGMS1, SGMS2 | BLM 1163/4885LMNA 507/4885PTPN1 3475/4885 |
| US-20100330154-A1 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS | LIPA, CETP, SGMS1 | BLM 892/4885LMNA 62/4885PTPN1 3379/4885 |
| US-20160151282-A1 | AMPHOTERIC LIPOSOME FORMULATIONS | LIPA, SGMS1, SGMS2 | BLM 1233/4885LMNA 741/4885PTPN1 3140/4885 |
| US-20140178462-A1 | AMPHOTERIC LIPOSOMES COMPRISING NEUTRAL LIPIDS | LIPA, CETP, SGMS1 | BLM 892/4885LMNA 62/4885PTPN1 3379/4885 |
| US-20080089932-A1 | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome | LIPA, SGMS1, SGMS2 | BLM 1163/4885LMNA 507/4885PTPN1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.